

Tillotts Pharma Transfers of Value in 2018 to Turkish Healthcare Professionals and Healthcare Organisations

Date of publication: June 2019

	Full Name (Art. 1.01)	HCPs: City of Principal Practice HCOs: city where registered (Art. 3)	Country of Principal Practice (Schedule 1)	Principal Practice Address (Art. 3)	Donations and Grants to HCOs (Art. 3.01.1.a)	Contribution to costs of Events (Art. 3.01.1.b & 3.01.2.a)			Fee for service and consultancy (Art. 3.01.1.c & 3.01.2.c)			
						Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the contract, including travel & accommodation relevant to the contract		
HCPs	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)											
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons											
	Aggregate amount attributable to transfers of value to such Recipients					N/A	N/A			10154 TRY	1796 TRY	
	Number of Recipients in aggregate disclosure					N/A	N/A			1	1	
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02					N/A	N/A			100%	100%	
HCOs	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)											
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons											
	Aggregate amount attributable to transfers of value to such Recipients											
	Number of Recipients in aggregate disclosure											
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02											
R & D	AGGREGATE DISCLOSURE											
	Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1											

Methodological Notes

Disclosure by Tillotts Pharma of payments to Turkish healthcare professionals and healthcare organisations in 2018

The European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure Code mandates the public disclosure in 2019 of certain transfers of value made during 2018 to European healthcare professionals and healthcare organisations. Tillotts Pharma is publishing such transfers of value made in 2018 to Turkish healthcare professionals and Turkish healthcare organisations on the website of Tillotts Pharma, www.tillotts.com, consistent with the EFPIA Disclosure Code.

The methodological notes below explain the data Tillotts Pharma have disclosed and how the data have been prepared, to assist the reader's understanding.

VAT

VAT is excluded from all disclosures of transfer of value.

Currency

All disclosures are made in Turkish Lira (TRY). Where the original payment was made in another currency, the sum was converted to Lira at 2018 annual average exchange rate.

Consolidated Disclosures of the Corporate Group and Cross-border Payments

The disclosures represent the consolidated transfers of value made by the Tillotts Pharma corporate group in line with the EFPIA Disclosure Code's dictate that separate entities belonging to the same multinational company (which could be the parent company and subsidiary company) shall be deemed to constitute a single company. In 2018, all transfers of value represent payments made by Tillotts Pharma AG.

Multi-year contracts

Where multi-year contracts are included in the disclosure of transfer of value made by Tillotts Pharma in 2018, the disclosures related to these multi-year contracts represent the payments made in calendar year 2018 under such contracts.

Data Protection

Consent to disclose data

In countries where it is required by applicable data protection laws, Tillotts has taken all reasonable steps to obtain consents from the HCPs, and HCOs, as applicable, to publicly disclose payments and other transfers of value. In accordance with EFPIA guidance, partial consents are not acceptable. If consent is not provided, the data will be reported on an aggregate level only.

Consent collection and withdrawal

Tillotts respects applicable data protection laws. If a stakeholder withdraws the provided consent, Tillotts will adjust the publication accordingly within a reasonable time.

Data included

The data disclosed by Tillotts Pharma is consistent with the requirements of the EFPIA Disclosure Code. The data can be categorised as follows:

Payment of consultants who provide services to Tillotts Pharma

Disclosed data includes the payment of honoraria, direct and indirect to Turkish healthcare professionals who provided services to Tillotts Pharma during 2018. The disclosure data also includes reasonable and necessary expenses related to the services, such as travel and accommodation costs.